{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-037749","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.535098+00:00","generated_at":"2026-06-17T12:45:44.491028+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AbbVie amends revolver: commitments raised to $5.0B, maturity extended to 2028","bullets":["Revolving credit facility commitments increased from $4.0B to $5.0B.","Maturity date extended from August 27, 2024 to March 28, 2028.","Facility remains unsecured; JPMorgan Chase continues as administrative agent.","Second Amended and Restated Revolving Credit Agreement dated March 28, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-037749","json":"https://secwatch.observer/filing/0001104659-23-037749.json","markdown":"https://secwatch.observer/filing/0001104659-23-037749.md","text":"https://secwatch.observer/filing/0001104659-23-037749.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/0001104659-23-037749-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/tm2310687d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:45:44.491028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64d89b42fb57f7862f10da7e20730b402c2474e3","claim":"AbbVie Inc. amended revolving credit of $5.0 billion with JPMorgan Chase Bank, N.A. maturing March 28, 2028.","evidence_excerpt":"(i) increases the unsecured revolving credit facility commitments from $4.0 billion to $5.0 billion and (ii) extends the maturity date of the facility from August 27, 2024 to March 28, 2028.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/0001104659-23-037749-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$5.0 billion"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Maturity","value":"March 28, 2028"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"cc63df8021f7037c5d6fec515cb424b8c13e4049","claim":"AbbVie Inc. entered into Second Amended and Restated Revolving Credit Agreement with JPMorgan Chase Bank, N.A. valued at $5.0 billion (effective 2023-03-28).","evidence_excerpt":"On March 28, 2023 (the “Effective Date”), AbbVie Inc. (“AbbVie”) entered into an amended and restated revolving credit agreement (the “Second Amended and Restated Revolving Credit Agreement”) among AbbVie, as borrower, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A., as administrative agent","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465923037749/0001104659-23-037749-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"JPMorgan Chase Bank, N.A."},{"label":"Value","value":"$5.0 billion"},{"label":"Effective","value":"2023-03-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}